Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Jacob T. Mitchell

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5370-9692; OpenAlex author ID A5023468878; NIH RePORTER profile ID 78107195. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
62
Papers, trials and grants by year

2022: 2 papers · 2023: none · 2024: 2 papers, 1 grant · 2025: 3 papers · 2026: 2 papers

Papers 9

  1. Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0331↗
  2. A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC. Co-author DOI 10.1158/2326-6066.cir-25-0545↗
  3. CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial. First author DOI 10.1016/j.isci.2024.111569↗
  4. Spatial profiling of human pancreatic ductal adenocarcinoma reveals molecular alterations associated with venous invasion. Co-author DOI 10.1126/scitranslmed.ady7524↗
  5. Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells. Co-author DOI 10.1158/1078-0432.ccr-24-2183↗
  6. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  7. Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.179292↗
  8. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
  9. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture Co-author DOI 10.1101/2022.07.14.500096↗

Grants 1

  1. Investigation of Immunotherapy-induced Alterations to Cellular Communication Networks in Pancreatic Ductal Adenocarcinoma F31CA284525↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elana Judith Fertig · 9 shared papers, 2022–2026 · strength 1.47
  2. Luciane Tsukamoto Kagohara · 7 shared papers, 2022–2026 · strength 1.14
  3. Elizabeth M. Jaffee · 7 shared papers, 2022–2026 · strength 1.10
  4. Won Jin Ho · 4 shared papers, 2024–2026 · strength 0.74
  5. Robert A. Anders · 4 shared papers, 2022–2026 · strength 0.71
  6. Lei Zheng · 5 shared papers, 2022–2026 · strength 0.71
  7. Jacquelyn W. Zimmerman · 5 shared papers, 2022–2026 · strength 0.71
  8. Dimitrios N. Sidiropoulos · 4 shared papers, 2022–2025 · strength 0.57
  9. Jae Woo Lee · 3 shared papers, 2024–2026 · strength 0.56
  10. Jin Peng He · 4 shared papers, 2022–2026 · strength 0.54
  11. Janelle Marie Montagne · 3 shared papers, 2022–2026 · strength 0.50
  12. Laura DeLong Wood · 3 shared papers, 2022–2025 · strength 0.45
  13. Samantha R. Guinn · 3 shared papers, 2022–2026 · strength 0.44
  14. Richard Andrew Burkhart · 3 shared papers, 2022–2026 · strength 0.44
  15. Dung Thi Le · 2 shared papers, 2024–2026 · strength 0.39
  16. Katherine M. Bever · 2 shared papers, 2024–2026 · strength 0.39
  17. Daniel James Salas-Escabillas · 2 shared papers, 2025 · strength 0.38
  18. Christopher L. Wolfgang · 3 shared papers, 2022–2024 · strength 0.35
  19. Benedict Kinny‐Köster · 3 shared papers, 2022–2024 · strength 0.35
  20. Nicole Groß · 2 shared papers, 2024–2026 · strength 0.35
  21. Yeonju Cho · 2 shared papers, 2024–2026 · strength 0.35
  22. Hao Wang · 2 shared papers, 2022–2026 · strength 0.34
  23. Daniel J. Zabransky · 2 shared papers, 2024–2026 · strength 0.33
  24. David Tsai Ting · 2 shared papers, 2022–2024 · strength 0.25
  25. Toni T. Seppälä · 2 shared papers, 2022–2024 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.